Myoclonic dystonia 15

Summary

Myoclonic dystonia 15 (MONDO:0011844) is a disease. A subtype of myoclonus-dystonia syndrome — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	myoclonic dystonia 15
Mondo ID	MONDO:0011844
MeSH	C538002
OMIM	607488
Orphanet	210566
DOID	DOID:0090035
UMLS	C1843786
MedGen	334492
GARD	0009629
Is cancer (heuristic)	no

Also known as: dystonia 15, myoclonic · dystonia-15, myoclonic · DYT15 · myoclonic dystonia type 15

Disease family

This is a subtype of myoclonus-dystonia syndrome. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › movement disorder › extrapyramidal and movement disease › dystonic disorder › inherited dystonia › combined dystonia › myoclonus-dystonia syndrome › myoclonic dystonia 15

Related subtypes (2): myoclonic dystonia 11, myoclonic dystonia 26

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.